Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.59 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.59 |
| ▸ | TSPO | P30536 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20827760 | 1.00 | HCRTR1 (0.59) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2122715 | 0.94 | HCRTR1 (0.59) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2616573 | 0.92 | HCRTR1 (0.58) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2616575 | 0.92 | HCRTR1 (0.57) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2616571 | 0.91 | HCRTR1 (0.56) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2616574 | 0.91 | HCRTR1 (0.59) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2616576 | 0.90 | HCRTR1 (0.57) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2616558 | 0.88 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL2616554 | 0.88 | HCRTR1 (0.55) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2123419 | 0.87 | HCRTR1 (0.63) | HCRTR1HCRTR2TSPOOPRK1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | claimed |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | Inserm (Institut National de la Santa et de la Recherche Medicale) (FR) | 2021-01-19 | — | — | US | disclosed |
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, GPR119 | HCRTR1 2/4885HCRTR2 1/4885TSPO 339/4885 |
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | HCRTR1 3720/4885HCRTR2 2843/4885TSPO 1832/4885 |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | OXTR, OGFR, OXGR1 | HCRTR1 18/4885HCRTR2 14/4885TSPO 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.